drug

famotidine

Famotidine
MeSH D015738
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Jesper Ekelund
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Famotidine in Schizophrenia
NCT01946295Phase 2, Phase 3Unknown
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
NCT00565175Phase 4Completed

KOLs & investigators

2
Jesper Ekelund, MD-PhD
Jesper Ekelund, MD, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Jesper Ekelund
company
trial
Famotidine in Schizophrenia
PHASE2, PHASE3
trial
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
PHASE4
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Bronchiolitis Obliterans Syndrome
indication
KOL
Jesper Ekelund, MD-PhD
KOL score —
person
Jesper Ekelund, MD, PhD
KOL score —
person